Ovarian Cancer

Ovarian cancer is a group of diseases characterized by malignant growths arising from the tissues of the ovary. It is histologically and molecularly diverse, with the most common type, Epithelial Ovarian Cancer (EOC), accounting for about 90% of cases. Other types include Germ Cell Tumors and Sex Cord-Stromal Tumors. Ovarian cancer is often referred to as a "silent killer" because its symptoms can be vague and non-specific, leading to delayed diagnosis. Approximately 75-80% of women are diagnosed at an advanced stage (Stage III or IV) when the cancer has spread beyond the ovaries. The prognosis is highly dependent on the stage at diagnosis, tumor grade, histological subtype, and the success of initial surgery. While long-term survival is possible, especially for early-stage disease, advanced ovarian cancer has a high rate of recurrence and is often managed as a chronic illness.

Symptoms

Persistent abdominal or pelvic pain
Persistent bloating or increased abdominal size
Difficulty eating or feeling full quickly (early satiety)
Urinary symptoms (urgency or frequency)
Unexplained fatigue
Changes in bowel habits (constipation or diarrhea)
Unexplained weight loss
Pain during intercourse (dyspareunia)
Back pain
Abnormal vaginal bleeding (especially postmenopausal)
Nausea and indigestion
Shortness of breath (can be due to fluid around the lungs)
Severe abdominal pain (emergency symptom)
Nausea, vomiting, and inability to pass gas or stool (emergency symptom, signs of bowel obstruction)
Significant shortness of breath (emergency symptom, signs of large pleural effusion or ascites)
Acute abdominal swelling (emergency symptom)

Causes & Risk Factors

Germline genetic mutations, particularly in BRCA1 and BRCA2 genes, which significantly increase lifetime risk
Mutations in Lynch Syndrome genes (MLH1, MSH2, MSH6, PMS2, EPCAM)
Mutations in other genes like BRIP1, RAD51C, RAD51D, associated with a moderate increase in risk
Repeated ovulation and subsequent epithelial repair (Incessant Ovulation Theory)
Chronic inflammation, potentially from conditions like endometriosis or pelvic inflammatory disease (Inflammation Theory)
Origin from precursor lesions in the fimbriated end of the fallopian tube, especially for high-grade serous ovarian cancers (Fallopian Tube Origin Theory)
The exact cause for the majority of ovarian cancers (sporadic cases) is not fully understood
Increased age, most common after menopause (Non-Modifiable)
Inherited mutations in genes such as BRCA1 and BRCA2 (Non-Modifiable)
Lynch syndrome (Non-Modifiable)
Family history of ovarian, breast, or colorectal cancer in a first-degree relative (Non-Modifiable)
Previous diagnosis of breast, uterine, or colorectal cancer (Non-Modifiable)
Early menarche (before age 12) (Non-Modifiable)
Late menopause (after age 52) (Non-Modifiable)
Nulliparity (never having been pregnant) (Non-Modifiable)
Endometriosis, associated with increased risk of clear cell and endometrioid ovarian cancers (Non-Modifiable)
Use of estrogen-only Hormone Replacement Therapy (HRT) after menopause (Modifiable)
Obesity (Body Mass Index of 30 or greater) (Modifiable)
Perineal use of talcum powder (Possible / Uncertain)
Smoking, associated with increased risk of the mucinous subtype (Possible / Uncertain)
In Vitro Fertilization (IVF), with inconsistent evidence (Possible / Uncertain)
Each full-term pregnancy provides a risk reduction (Protective)
Breastfeeding has a protective effect (Protective)
Use of combined oral contraceptives, particularly for 5 years or more, significantly reduces risk (Protective)
Tubal ligation reduces risk (Protective)
Hysterectomy reduces risk (Protective)
Salpingectomy (removal of fallopian tubes) significantly reduces risk (Protective)
Risk-Reducing Salpingo-oophorectomy (RRSO) for high-risk individuals (Protective)

Diagnosis

Detailed review of symptoms, focusing on frequency, persistence, and onset
Personal medical history, including endometriosis or other cancers
Detailed family history of cancer (ovarian, breast, colorectal, uterine)
Reproductive and menstrual history
Abdominal examination to assess for a mass, fluid in the abdomen (ascites), or tenderness
Pelvic examination (bimanual and speculum) to assess for an adnexal mass
Blood test for Cancer Antigen 125 (CA-125), a tumor marker (note: not a screening tool for the general population and can be elevated in benign conditions)
Blood test for Human Epididymis Protein 4 (HE4), another tumor marker often used with CA-125
Risk of Ovarian Malignancy Algorithm (ROMA), combining CA-125, HE4, and menopausal status
Blood tests for germ cell tumor markers (Alpha-fetoprotein, human chorionic gonadotropin, lactate dehydrogenase) for suspected germ cell tumors
Transvaginal Ultrasound as the primary imaging to evaluate an adnexal mass and characterize its features
Computed Tomography (CT) of Abdomen and Pelvis with contrast for staging and assessing metastatic disease
Magnetic Resonance Imaging (MRI) for further characterization of an indeterminate adnexal mass
Positron Emission Tomography (PET) Scan, typically used to detect recurrence rather than initial diagnosis
Definitive diagnosis is always histological, requiring a tissue sample obtained during surgery (laparotomy or laparoscopy) or biopsy
Differential diagnosis includes benign ovarian cysts, uterine fibroids, tubo-ovarian abscess, ectopic pregnancy, diverticular disease, Irritable Bowel Syndrome (IBS), primary peritoneal cancer, and metastatic cancer to the ovary
Current guidelines recommend measuring serum CA-125 for women with persistent or frequent symptoms; if elevated, an ultrasound should be performed
If ultrasound suggests ovarian cancer, urgent referral to a gynecologic oncology service is recommended
All patients with suspected ovarian malignancy should be managed by a multidisciplinary team led by a gynecologic oncologist

Treatment Options

Staging and Cytoreductive (Debulking) Surgery, which is the cornerstone of treatment for most types and stages
Surgical procedures typically include total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and sampling of lymph nodes and peritoneal surfaces
The goal of surgery is optimal cytoreduction, aiming for no visible residual disease or residual nodules less than 1 cm
Fertility-Sparing Surgery may be an option for some young women with early-stage, low-grade epithelial tumors or certain germ cell tumors
Minimally Invasive Surgery (Laparoscopy/Robotic) can be used for staging in early-stage disease and for risk-reducing surgery
Chemotherapy, with a platinum-based agent (carboplatin) combined with a taxane (paclitaxel) as the standard of care for epithelial ovarian cancer
Chemotherapy can be given intravenously (IV) or sometimes intraperitoneally (IP)
Chemotherapy is administered as adjuvant therapy (after primary surgery) or neoadjuvant therapy (before surgery) for advanced disease
PARP Inhibitors (e.g., olaparib, niraparib, rucaparib) used as maintenance therapy for women who have responded to platinum-based chemotherapy, especially those with BRCA mutations or homologous recombination deficiencies
Anti-angiogenesis Therapy (e.g., bevacizumab), which inhibits vascular endothelial growth factor (VEGF), can be added to chemotherapy and continued as maintenance therapy
Watchful Waiting / Surveillance may be considered for some borderline ovarian tumors or select cases of early-stage, low-grade epithelial ovarian cancer after fertility-sparing surgery
Regular physical and pelvic exams during follow-up
Monitoring of CA-125 levels (if initially elevated) during follow-up
Imaging (CT or PET scan) as clinically indicated for symptoms or rising tumor markers during follow-up
Referral to and management by a gynecologic oncologist for any woman with a pelvic mass suspected to be ovarian cancer

Frequently Asked Questions

What is the difference between an ovarian cyst and ovarian cancer?

An ovarian cyst is a common, often benign (non-cancerous) fluid-filled sac that forms on the ovary. Ovarian cancer, on the other hand, is a malignant (cancerous) growth of cells that arises from the ovary. While some complex cysts may require further investigation, most ovarian cysts are not cancerous. Imaging and blood tests help evaluate an ovarian mass, but a definitive diagnosis of cancer always requires a tissue sample, usually obtained during surgery.

If my CA-125 level is normal, does that mean I don't have ovarian cancer?

Not necessarily. While CA-125 is a tumor marker often elevated in ovarian cancer, it can be normal in up to 50% of early-stage ovarian cancers. Therefore, a normal CA-125 level does not rule out ovarian cancer, especially if you are experiencing persistent symptoms.

If my CA-125 level is high, does that mean I have ovarian cancer?

A high CA-125 level does not automatically mean you have ovarian cancer. CA-125 can be elevated in many benign conditions, such as endometriosis, uterine fibroids, pelvic inflammatory disease, pregnancy, and even during menstruation. If your CA-125 is elevated, your doctor will likely recommend further tests, such as an ultrasound, to investigate the cause.

Should I be screened for ovarian cancer during my annual check-up?

For women at average risk and without symptoms, routine screening for ovarian cancer with tests like CA-125 or transvaginal ultrasound is not recommended by major medical organizations. Studies have shown that these screening methods do not reduce mortality from ovarian cancer and can lead to a significant number of false-positive results, causing unnecessary anxiety and potentially harmful surgeries.

I have a family history of breast cancer. Am I at higher risk for ovarian cancer?

Yes, having a family history of breast cancer, especially in a first-degree relative (mother, sister, daughter), can increase your risk for ovarian cancer. This is often due to inherited genetic mutations, such as in the BRCA1 and BRCA2 genes, which increase the risk for both breast and ovarian cancers. It is important to discuss your family history with your doctor to assess your personal risk.

Should I get genetic testing for BRCA mutations?

Genetic testing for BRCA mutations is recommended if you have a strong family history of ovarian, breast, or other related cancers, or if you have been diagnosed with epithelial ovarian cancer. Discussing your personal and family medical history with your doctor or a genetic counselor can help determine if genetic testing is appropriate for you.

What is a gynecologic oncologist and why do I need to see one?

A gynecologic oncologist is a doctor who specializes in cancers of the female reproductive system, including ovarian cancer. They have advanced training in both surgery and chemotherapy for these specific cancers. If ovarian cancer is suspected, it is strongly recommended that you be managed by a multidisciplinary team led by a gynecologic oncologist, as their specialized expertise is associated with better outcomes.

What does 'debulking' or 'cytoreductive' surgery mean?

'Debulking' or 'cytoreductive' surgery is a procedure to remove as much of the cancerous tumor as possible. For ovarian cancer, this typically involves removing the ovaries, fallopian tubes, uterus, and often other affected tissues like the omentum and lymph nodes. The goal is to leave no visible cancer or only very small residual tumors, as the amount of cancer remaining after surgery is a major factor in prognosis.

Will I need a hysterectomy as part of my treatment?

For most types and stages of ovarian cancer, a total abdominal hysterectomy (removal of the uterus) is typically part of the staging and cytoreductive surgery. However, in very specific cases of early-stage, low-grade tumors in younger women, fertility-sparing surgery (removing only the affected ovary and fallopian tube) may be an option.

Can my fertility be preserved if I have ovarian cancer?

Fertility-sparing surgery may be an option for some young women with early-stage (Stage IA), low-grade epithelial tumors or certain germ cell tumors. This involves removing only the affected ovary and fallopian tube, preserving the uterus and the other ovary. This decision is made after careful consideration with your gynecologic oncologist, balancing cancer treatment with fertility preservation goals.

What are the side effects of chemotherapy for ovarian cancer?

Common side effects of chemotherapy for ovarian cancer can include nausea, vomiting, fatigue, hair loss, and myelosuppression (a decrease in blood cell production leading to anemia, increased risk of infection, and bruising/bleeding). Other side effects may include peripheral neuropathy (numbness or tingling in hands and feet) and mucositis (inflammation of the mouth and digestive tract lining). Your care team will discuss strategies to manage these side effects.

Will I lose my hair during treatment?

Many chemotherapy regimens used for ovarian cancer, particularly those involving taxanes like paclitaxel, commonly cause hair loss. This typically includes hair on the scalp, as well as eyebrows, eyelashes, and body hair. Hair usually grows back after treatment is completed, though it may have a different texture or color initially.

What is a PARP inhibitor and how does it work?

PARP inhibitors are a type of targeted therapy used as maintenance treatment for some women with ovarian cancer, especially those who have responded to platinum-based chemotherapy. They work by blocking an enzyme called poly (ADP-ribose) polymerase (PARP), which helps repair damaged DNA in cancer cells. By inhibiting PARP, these drugs prevent cancer cells from repairing their DNA, leading to their death. They are particularly effective in patients with BRCA mutations or other homologous recombination deficiencies.

What is the difference between neoadjuvant and adjuvant chemotherapy?

Neoadjuvant chemotherapy is given before surgery, typically for patients with advanced ovarian cancer to shrink tumors and make surgery more effective or possible. Adjuvant chemotherapy is given after primary surgery to kill any remaining cancer cells and reduce the risk of recurrence.

Will I go into menopause immediately after surgery?

If you are premenopausal and have both ovaries removed during surgery (bilateral oophorectomy), you will experience immediate surgical menopause. This can lead to an abrupt onset of menopausal symptoms such as hot flashes, vaginal dryness, and mood changes. Your doctor can discuss ways to manage these symptoms.

What is the chance my ovarian cancer will come back after treatment?

Ovarian cancer has a high rate of recurrence, especially for women diagnosed at an advanced stage. Approximately 70-80% of women with advanced ovarian cancer will experience a recurrence. Your specific risk depends on factors like the stage of your cancer at diagnosis, the type of cancer, and how well you responded to initial treatment.

How is recurrent ovarian cancer treated?

Recurrent ovarian cancer is often treated with further chemotherapy or targeted agents. While generally not considered curable, the goal of treatment shifts to controlling the disease, managing symptoms, and maintaining your quality of life. Treatment options will depend on how long you were in remission, previous treatments, and your overall health.

Can diet or lifestyle changes help treat my cancer or prevent it from recurring?

While maintaining a healthy weight, eating a balanced diet, and engaging in physical activity are generally beneficial for overall health, there is no definitive evidence that specific diet or lifestyle changes can treat ovarian cancer or prevent its recurrence. However, these factors can contribute to your overall well-being and help manage treatment side effects. Always discuss any significant diet or lifestyle changes with your healthcare team.

What is the role of clinical trials in ovarian cancer treatment?

Clinical trials are research studies that test new treatments or new ways of using existing treatments. They play a crucial role in advancing ovarian cancer care by exploring new therapies, improving existing ones, and finding better ways to prevent, detect, and manage the disease. Your doctor can discuss if a clinical trial might be a suitable option for you.

How is my stage of cancer determined?

The stage of ovarian cancer is determined during surgery. This involves examining the extent of the cancer's spread within the abdomen and pelvis, including the ovaries, fallopian tubes, uterus, omentum, lymph nodes, and peritoneal surfaces. This information helps your medical team plan the most appropriate treatment.

Can I use hormone replacement therapy after treatment for ovarian cancer?

The use of hormone replacement therapy (HRT) after treatment for ovarian cancer is a complex decision that should be discussed thoroughly with your gynecologic oncologist. While HRT can help manage menopausal symptoms, its safety in women with a history of ovarian cancer, particularly certain types, needs careful consideration due to potential risks.

What is opportunistic salpingectomy and should I consider it?

Opportunistic salpingectomy is the removal of the fallopian tubes during another benign pelvic surgery, such as a hysterectomy or tubal ligation. This procedure is increasingly recommended for average-risk women because a significant body of evidence suggests that many high-grade serous ovarian cancers (the most common type) may originate in the fallopian tubes. You should discuss with your doctor if this procedure is appropriate for you during any planned pelvic surgery.